- conflicts or gaps
- [[{"issue": {"value": "Total funding conflict: LinkedIn reports $73.1M total; Tracxn reports $35.8M; BIO Investment & Growth Summit 2026 page claims $80M secured; YC founder profile states raised more than $30M.", "source_urls": ["https://www.linkedin.com/company/kernal-biologics-inc.", "https://tracxn.com/d/companies/kernalbiologics/__hR5SaE-r3pguFxYVILlPnvErTbqy84SF_I5hAhqYPiY", "https://bigs.bio.org/participating-companies/kernal-bio", "https://www.ycombinator.com/companies/kernal-biologics"]}}, {"issue": {"value": "Employee count conflict: YC lists team size 20; LinkedIn lists 15 employees; LeadIQ estimates ~19 as of May 2026.", "source_urls": ["https://yc-oss.github.io/api/batches/summer-2020/kernal-biologics.json", "https://www.linkedin.com/company/kernal-biologics-inc.", "https://leadiq.com/c/kernal-biologics/5a1dc3972300005400c557ad/employee-directory"]}}, {"issue": {"value": "Founder roster conflict: Company about page lists Yusuf Erkul, Burak Yilmaz, and Jeff Ozdemir as cofounders; Tracxn and FounderTrace also list Catherine Moroski Erkul as cofounder but she is absent from company leadership page.", "source_urls": ["https://kernalbio.com/about", "https://tracxn.com/d/companies/kernal-biologics/__hR5SaE-r3pguFxYVILlPnvErTbqy84SF_I5hAhqYPiY/founders-and-board-of-directors", "https://foundertrace.com/companies/kernal_biologics/"]}}, {"issue": {"value": "Lead program shift: 2022 Series A press release emphasized KR-335 immuno-oncology IND; 2025–2026 public communications emphasize KR-402 in vivo CAR-T as lead program supported by ARPA-H.", "source_urls": ["https://www.prnewswire.com/news-releases/kernal-biologics-announces-25m-series-a-financing-to-advance-its-mrna-2-0-technology-for-oncology-301581933.html", "https://www.businesswire.com/news/home/20251007266824/en/Kernal-Bio-Awarded-up-to-%2448-Million-from-ARPA-H-to-Develop-Lower-Cost-in-vivo-CAR-T-cell-Therapies-for-Hematological-Cancers-and-Autoimmune-Disease", "https://bigs.bio.org/participating-companies/kernal-bio"]}}, {"issue": {"value": "Headquarters wording varies: YC OSS API lists Boston, MA; LinkedIn and company site emphasize Cambridge, MA; LeadIQ lists 700 Main Street, Cambridge, MA 02139.", "source_urls": ["https://yc-oss.github.io/api/batches/summer-2020/kernal-biologics.json", "https://www.linkedin.com/company/kernal-biologics-inc.", "https://leadiq.com/c/kernal-biologics/5a1dc3972300005400c557ad/employee-directory"]}}, {"issue": {"value": "YC Summer 2020 investment amount: LinkedIn lists $125k seed on 2020-06-01; standard YC S20 deal was widely reported as $150k — Kernal-specific primary filing not independently verified.", "source_urls": ["https://www.linkedin.com/company/kernal-biologics-inc.", "https://www.ycombinator.com/companies/kernal-biologics"]}}, {"issue": {"value": "ARPA-H $48M is an up-to milestone-based award, not necessarily fully received upfront; sources differ on whether to count full amount in total funding.", "source_urls": ["https://www.businesswire.com/news/home/20251007266824/en/Kernal-Bio-Awarded-up-to-%2448-Million-from-ARPA-H-to-Develop-Lower-Cost-in-vivo-CAR-T-cell-Therapies-for-Hematological-Cancers-and-Autoimmune-Disease", "https://tracxn.com/d/companies/kernalbiologics/__hR5SaE-r3pguFxYVILlPnvErTbqy84SF_I5hAhqYPiY", "https://www.linkedin.com/company/kernal-biologics-inc."]}}, {"issue": {"value": "No clinical trial registration or IND approval publicly confirmed in fetched primary sources; pipeline appears preclinical/clinical-stage transition.", "source_urls": ["https://www.prnewswire.com/news-releases/kernal-biologics-announces-25m-series-a-financing-to-advance-its-mrna-2-0-technology-for-oncology-301581933.html", "https://www.businesswire.com/news/home/20251007266824/en/Kernal-Bio-Awarded-up-to-%2448-Million-from-ARPA-H-to-Develop-Lower-Cost-in-vivo-CAR-T-cell-Therapies-for-Hematological-Cancers-and-Autoimmune-Disease", "https://kernalbio.com/pipeline"]}}, {"issue": {"value": "Preclinical efficacy claims (>90% delivery efficiency, B-cell depletion within a week, 100-fold manufacturing cost reduction) are company-reported and not independently verified in fetched sources.", "source_urls": ["https://yc-oss.github.io/api/batches/summer-2020/kernal-biologics.json", "https://www.businesswire.com/news/home/20251007266824/en/Kernal-Bio-Awarded-up-to-%2448-Million-from-ARPA-H-to-Develop-Lower-Cost-in-vivo-CAR-T-cell-Therapies-for-Hematological-Cancers-and-Autoimmune-Disease", "https://bigs.bio.org/participating-companies/kernal-bio"]}}, {"issue": {"value": "Early seed rounds (2016, 2018, 2020) have undisclosed amounts and investors on Tracxn/LinkedIn; Crunchbase profile not retrieved in this research.", "source_urls": ["https://tracxn.com/d/companies/kernalbiologics/__hR5SaE-r3pguFxYVILlPnvErTbqy84SF_I5hAhqYPiY", "https://www.linkedin.com/company/kernal-biologics-inc."]}}]]
- source urls
- ["https://bigs.bio.org/participating-companies/kernal-bio", "https://foundertrace.com/companies/kernal_biologics/", "https://kernalbio.com/", "https://kernalbio.com/about", "https://kernalbio.com/pipeline", "https://leadiq.com/c/kernal-biologics/5a1dc3972300005400c557ad/employee-directory", "https://medcitynews.com/2022/07/amgen-joins-kernal-bios-25m-financing-as-the-startup-brings-mrna-2-0-to-cancer/", "https://synapse.patsnap.com/organization/2fb4b3c5745ae0f43296b7dce15c5e22", "https://tracxn.com/d/companies/kernal-biologics/__hR5SaE-r3pguFxYVILlPnvErTbqy84SF_I5hAhqYPiY/founders-and-board-of-directors", "https://tracxn.com/d/companies/kernalbiologics/__hR5SaE-r3pguFxYVILlPnvErTbqy84SF_I5hAhqYPiY", "https://www.biospace.com/policy/despite-mrna-vaccine-pullback-hhs-awards-48m-for-kernals-mrna-car-t-program", "https://www.businesswire.com/news/home/20251007266824/en/Kernal-Bio-Awarded-up-to-%2448-Million-from-ARPA-H-to-Develop-Lower-Cost-in-vivo-CAR-T-cell-Therapies-for-Hematological-Cancers-and-Autoimmune-Disease", "https://www.businesswire.com/news/home/20260430632818/en/Kernal-Biologics-to-Showcase-mRNA-2.0-Platform-and-T-Cell-Targeted-LNPs-for-In-Situ-CAR-T-Programming-at-ASGCT-2026", "https://www.cbinsights.com/company/kernal-biologics", "https://www.linkedin.com/company/kernal-biologics-inc.", "https://www.precisionmedicineonline.com/precision-oncology/arpa-h-awards-kernal-bio-48m-develop-vivo-car-t-cell-therapies", "https://www.prnewswire.com/news-releases/kernal-biologics-announces-25m-series-a-financing-to-advance-its-mrna-2-0-technology-for-oncology-301581933.html", "https://www.ycombinator.com/companies/kernal-biologics", "https://yc-oss.github.io/api/batches/summer-2020/kernal-biologics.json"]